AMTI - Earnings announcements

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial – AMT-101 appeared safe and well-tolerated – Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 06

SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company's oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Appli

- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to con